CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.